Le Lézard
Classified in: Health
Subjects: TDS, FVT

Bridge to Life Announces Abstract Presentations at The European Society for Transplantation's ELITA Summit 2024 in Madrid, Spain, April 18-20, 2024


CHICAGO, April 2, 2024 /PRNewswire/ -- Bridge to Life Ltd, a renowned market leader in organ preservation solutions, today announced the presentation of two accepted abstracts at the 2024 ELITA Summit under the auspices of The European Society for Transplantation. The conference is scheduled to take place in Madrid, Spain, from April 18-20, 2024.

Abstracts to highlight hypothermic oxygenated perfusion in liver transplants and use in Extended Criteria Grafts

Abstracts to be presented:

100 Hypothermic Oxygenated Perfusion liver transplants in a Portuguese Centre, Júlio Constantino, MD et al, to be presented by Dulce Diogo, MD, Unidade de Transplantação Hepática de Adultos - Serviço de Cirurgia Geral, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; Poster viewing session on Thursday 18 April 2024, 19:00 ? 20:30.

Single center evolution of DCD donor utilization for liver transplantation: from perceived marginality to routine and beyond, Matteo Ravaioli, MD et al, Hepatobiliary and Transplant Surgery, Policlinico Sant'Orsola ? IRCCS Azienda Ospedaliero, Universitaria di Bologna, Bologna, Italy; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna (Italy), Bologna, Italy; Poster viewing session on Friday 19 April 2024, 12:45 - 13:45.

About Bridge to Life Ltd

Bridge to Life Ltd is a market leader in organ preservation solutions, offering premier products such as Belzer UW, EasiSlush and the VitaSmart1 hypothermic oxygenated perfusion system.  With a strong focus on product quality, innovation and accessibility, the company serves and partners with leading Transplant Centers and Organ Procurement Offices (OPO) globally.

1 VitaSmart is CE Marked and available for sale in several markets outside of the United States. VitaSmart is not approved for sale in the US. The company successfully completed its pivotal, multicenter, randomized clinical study in the US in 2023 and expects to submit its Premarket Approval submission to FDA later this year.     

SOURCE Bridge to Life, Ltd.


These press releases may also interest you

at 20:00
The 5p- Society of North America, along with families and support organizations from over 95 countries, are bringing awareness of 5p Deletion Syndrome also known as 5p Minus (5p-)...

at 19:31
Alleva, a leading provider of electronic medical record (EMR) solutions, attended the first-ever East Coast TCIV conference last week in Palm Beach, Florida. The company's CEO, Steve McCall, Director of Sales, John David, and Manager of Strategic...

at 18:54
The Canadian Food Inspection Agency (CFIA) has confirmed the presence of emerald ash borer (EAB - Agrilus planipennis) in the City of Vancouver, British Columbia. These detections, which are outside of currently regulated areas for emerald ash borer...

at 18:35
Teva Pharmaceutical Industries Ltd. today announced that Richard Francis, Teva's President and CEO, will present at the 2024 Bank of America Healthcare Conference on Tuesday, May 14, 2024. The presentation will begin at 8:40 A.M. Pacific Time (11:40...

at 18:32
Total Point Healthcare Systems, Inc. is on a mission to bring quality, affordable medical care to the states of Texas, Missouri, and Arizona. Established by Jeffrey Love, a new investor with extensive experience in the tech ecosystem Bijaya Karki,...

at 18:15
Andlauer Healthcare Group Inc. ("AHG" or the "Company") today reported its financial results for the three-month period ended March 31, 2024 ("Q1 2024"). Q1 2024 Summary Revenue totaled $161.1 million, a decrease of 2.2% from $164.8 million for the...



News published on and distributed by: